BioSpace News Archive

SciSparc Ltd. today announced that Clearmind Medicine Inc. (“Clearmind”) (CSE: CMND), (OTC: CMNDF), (FSE: CWY0), has filed a provisional patent application related to metabolic syndromes including obesity, regarding the Company’s collaboration with Clearmind.

Alvotech (NASDAQ: ALVO) and STADA Arzneimittel AG (STADA), announced today the launch of Hukyndra®, a high-concentration, low-volume, citrate-free formulation, biosimilar to Humira® (adalimumab), in Switzerland.

NextCure, Inc. (Nasdaq: NXTC today announced that it will present at the Ladenburg Thalmann Healthcare Conference in New York City on Thursday, September 29th at 10 am ET.

Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the Ladenburg Thalmann Healthcare Conference on Thursday, September 29 at 12:30 p.m. E.T.

Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company will be participating in-person in the Ladenburg Thalmann 2022 Healthcare Conference, which is taking place at the Sofitel Hotel in New York, NY.

PepGen Inc., a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, announced the appointment of Habib Joseph Dable to its Board of Directors.

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on leveraging its proprietary Lip’ral platform to augment therapeutics through effective oral delivery by developing differentiated products relative to standard of care, announced today that it will present at the Ladenburg Thalmann 2022 Healthcare Conference on September 29 in New York.

Virios Therapeutics, Inc. announced the closing of its previously announced underwritten public offering of 10.0 million shares of its common stock at a public offering price of $0.50 per share, for gross proceeds of $5.0 million, before deducting underwriting discounts, commissions and offering expenses.

Solarvest BioEnergy Inc. (TSXV: SVS) (“Solarvest” or the “Company”) announces that pursuant to the Company’s existing Stock Option Plan, a total of 1,000,000 incentive stock options have been granted to a consultant of the Company

DENTSPLY SIRONA Inc. announced that Glenn Coleman has been appointed Executive Vice President and Chief Financial Officer, effective September 26, 2022.